A report commissioned by the United Kingdom government has found data to corroborate a widely held belief: R&D collaborations with British universities are expensive. Yet with such institutions performing world-class science--and tax breaks and funding schemes offsetting the upfront costs--Big Pharma is lining up to strike deals. Just ask Pfizer.
Calgary-based Resverlogix said it has closed a deal to license greater China rights to clinical stage cardiovascular drug RVX-208 to China's Shenzhen Hepalink Pharmaceutical, putting its future on an known candidate now billed as a new treatment for atherosclerosis.
Profound Medical went public on the Toronto Stock Exchange last month and raised $25 million in June. Now, it's partnered with Royal Philips to develop its novel, minimally invasive prostate gland ablation tool to be used on Philips' MRI systems.
Just days ago, GlaxoSmithKline signed the first big deal with the Francis Crick Institute. And now a high-profile examination of the state of play of partnering in academic research circles, the Dowling Report, says Glaxo is the single largest collaborator with academia in the U.K., for any industry.
Singapore-based ASLAN Pharmaceuticals has signed an understanding with the National Cancer Centre of Singapore (NCCS) to study novel combination therapies to treat gastric cancer, hepatocellular carcinoma and cholangiocarcinoma, in its second move in this month to explore wider avenues for its existing clinical trial candidates.
After scoring FDA approval last week for its finger-stick herpes test and striking its first deal to provide its tests for a private insurer, Theranos is teaming up with a managed care provider to offer its tests to Medicaid patients and snagging a CLIA waiver from the FDA for its herpes testing system.
Five Prime Therapeutics is buying to Inhibrx's early-stage cancer R&D, signing a deal worth up to $452.5 million to get its hands on an immuno-oncology project.
CROs Icon and Covance signed a pair of separate partnerships in the world of cancer diagnostics, each betting that new technologies in oncology testing will increase global demand.
Theranos has major ambitions--and, if you glance at the composition of its board, it's obvious that diagnostics cost-savings on the massive scale of the U.S. government is at the core of them. Now, it's made a first partnership that moves it toward realizing that goal. It will offer diagnostic testing through managed care provider AmeriHealth Caritas, which serves more than 6.6 million patients across 16 states and the District of Columbia--the bulk of whom are on Medicaid.
The Merck Global Health Innovation Fund invested $6 million in OpGen on the same day the microbial genetics specialist announced it will acquire AdvanDx, a maker of molecular tests for blood cultures.